Patent application number | Description | Published |
20120014404 | Apparatus and Method for Determining the Thermal Stability of Fluids - A thermal oxidation tester is shown for determining thermal stability of a fluid, particularly hydrocarbons when subjected to elevated temperatures. The tendency of the heated fluid to oxidize and (1) form deposits on a surface of a heater tube and (2) form solids therein, are both measured at a given flow rate, temperature and time. The measured results are used to determine whether a fluid sample passes or fails the test. Results of measurements are recorded in a memory device on one end of the heater tube on which the deposits were made. | 01-19-2012 |
20120014405 | Drop Counter And Flow Meter For Apparatus And Method For Determining The Thermal Stability Of Fluids - A thermal oxidation tester is shown for determining thermal stability of a fluid, particularly hydrocarbons when subjected to elevated temperatures. The tendency of the heated fluid to oxidize and (1) form deposits on a surface of a heater tube and (2) form solids therein, are both measured at a given flow rate, temperature and time. The measured results are used to determine whether a fluid sample passes or fails the test. Sample flow rate is important in the jet fuel thermal oxidation test. Current practice requires manual drop counting or flow confirmation with the use of volumetric glassware. An apparatus is described to precisely measure the flow rate and automatically perform flow rate check using a drip rate method and/or volumetric method. | 01-19-2012 |
20120014406 | CONTAINERS USED IN DETERMINING THE THERMAL STABILITY OF FUELS - A thermal oxidation tester is shown for determining thermal stability of a fluid, particularly hydrocarbons, when subjected to elevated temperatures. The tendency of the heated fluid to oxidize and (1) form deposits on a surface of a heater tube and (2) form solids therein which are both measured at a given flow rate, temperature and time. The measured results are used to determine whether a fluid sample passes or fails the test. Specifically constructed containers used in a thermal oxidation tester are shown. These containers (1) reduce physical contact to hydrocarbon test fuels, (2) reduce exposure to hydrocarbon fuel vapors, (3) reduce environmental impact by reducing chemical spills, and (4) improve overall work flow of test. | 01-19-2012 |
20120014407 | Auto Priming and Flushing an Apparatus for Determining the Thermal Stability of Fluids - A thermal oxidation tester is shown for determining thermal stability of a fluid, particularly hydrocarbons when subjected to elevated temperatures. The tendency of the heated fluid to oxidize and (1) form deposits on a surface of a heater tube and (2) form solids therein, are both measured at a given flow rate, temperature and time. The measured results are used to determine whether a fluid sample passes or fails the test. At the beginning of each test, the test sample is aerated with dry air until saturation. Simultaneously, the test equipment is primed to remove pockets of air there from. After each test, the test equipment is flushed to remove the test sample there from. | 01-19-2012 |
Patent application number | Description | Published |
20090170850 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones - The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula I | 07-02-2009 |
20110039897 | LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE - An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per litre of liquid composition, an effective amount of a humectant (such as glycerin) per litre of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste. | 02-17-2011 |
20130023569 | Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders - There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject. | 01-24-2013 |
20130190365 | Use of Deferiprone and Methods to Treat and/or Prevent Friedreich Ataxia Resulting from Intracellular Mishandling of Iron - A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron. | 07-25-2013 |
20140314676 | METHODS OF TREATMENT WITH DEFERIPRONE - The current application is directed to methods of treating or ameliorating myocardial ischemia, an acute coronary event, and a myocardial reperfusion injury comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient in need thereof. The application is also directed to reducing the risk for myocardial reperfusion injury as well as promoting the beneficial remodeling of cardiac tissue in a patient, comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient before, during or after reperfusion therapy. The application also includes methods of selecting a patient for treatment of reperfusion injury and subsequently treating the selected patient. | 10-23-2014 |